NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.7620
-0.0083 (-1.08%)
At close: May 19, 2026, 4:00 PM EDT
0.7550
-0.0070 (-0.92%)
After-hours: May 19, 2026, 4:50 PM EDT

NeuroSense Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
4.864.24.784.972.51
Research & Development
6.235.77.275.593.08
Total Operating Expenses
11.099.912.0510.555.59
Operating Income
-11.09-9.9-12.05-10.55-5.59
Total Non-Operating Income (Expense)
-0.04-0.311.940.061.55
Pretax Income
-11.13-10.21-10.11-10.49-4.04
Net Income
-11.13-10.21-10.11-10.49-4.04
Net Income to Common
-11.13-10.21-10.11-10.49-4.04
Shares Outstanding (Basic)
251914126
Shares Outstanding (Diluted)
251914126
Shares Change (YoY)
36.98%36.38%18.56%84.27%13.13%
EPS (Basic)
-0.44-0.54-0.74-1.07-0.65
EPS (Diluted)
-0.44-0.54-0.74-1.07-0.65
Shares Outstanding
32.5623.2315.3811.7810.94
Free Cash Flow
-7.68-10.14-8.38-7.69-1.56
Free Cash Flow Per Share
-0.30-0.54-0.61-0.67-0.25
EBITDA
-11.07-9.88-12.03-10.54-5.58
EBIT
-11.09-9.9-12.05-10.55-5.59
Updated Mar 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q